Pharmacies and Patients Unite: A Fight for Fairness in ADHD Medication Pricing
A groundbreaking agreement has just been reached, offering a lifeline to pharmacies and patients affected by a sudden price change in ADHD medication. The Pharmacy Guild of Australia and Takeda have joined forces to address the financial strain caused by the recent PBS price reduction of Vyvanse® to $55 per unit.
But here's the catch: Pharmacies can now breathe a sigh of relief as they are eligible for reimbursement on eligible Vyvanse® stock purchased before the price drop. This process is facilitated through their chosen CSO-accredited wholesaler, ensuring a seamless experience.
This initiative is not just about financial relief; it's about continuity of care. It acknowledges the indispensable role of wholesalers in Australia's medicine distribution network, ensuring patients receive the medications they rely on.
Pharmacies are urged to act promptly and contact their preferred wholesaler by the end of December 2025 to verify their stock as of November 30, 2025, and secure the rebate. This simple step is crucial for their financial well-being and patient support.
Anthony Tassone, Chair of the Guild's Health Economics and Policy Committee, praised the collaboration, emphasizing its fairness and long-term benefits. He acknowledged Takeda's understanding of the real-world implications of PBS price adjustments, especially when pharmacies maintain stock to assist patients amidst ADHD medication shortages.
Dave Peace, Takeda's General Manager for Australia and New Zealand, echoed this sentiment, highlighting the company's dedication to community pharmacy support. He addressed concerns regarding the Vyvanse® price change, assuring that pharmacies will not suffer financial losses.
Mr. Tassone further emphasized the significance of this agreement, stating, "Takeda's support has been invaluable in resolving this issue for community pharmacies nationwide. We look forward to ongoing partnerships with manufacturers and wholesalers to enhance patient access and pharmacy resilience." He also pointed out the avoidable nature of this situation, advocating for improved notice periods and supply chain assessments for future PBS pricing adjustments.
And this is where it gets intriguing: Is this agreement a one-time solution or a precedent for future pricing disputes? How can we ensure fair pricing and supply stability for essential medications? Share your thoughts below, and let's spark a conversation on this critical aspect of healthcare accessibility.
